 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > EntreMed, Inc.
 |
EntreMed, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
EntreMed cancer drugs are granted "orphan" status Aug 15 2001 06:28 AM PDT
EntreMed sells thalidomide royalty rights Aug 08 2001 05:41 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
EntreMed develops drugs that inhibit angiogenesis, the growth of new blood vessels. The firm's drugs may fight cancer, atherosclerosis, and certain types of blindness. Its lead drug candidates are Angiostatin and Endostatin, which have successfully blocked the growth of blood vessels in cancer tumors in mice. Another candidate in its pipeline is thalidomide, the infamous sedative pulled from the market in 1961 after being linked to birth defects. Celegene licensed from the firm THALOMID, a form of the drug approved to treat a type of leprosy. EntreMed continues to develop thalidomide as a potential cancer therapy. Subsidiary TheraMed is developing a drug delivery system based on a blood cell permeation device.
COMPETITION |
 |
AEterna Laboratories Inc. (AELA)
Boston Life Sciences, Inc. (BLSI)
SUGEN, Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 3.70
1-Yr. Sales Growth: (26.0)%
Employees: 101
Revenue per employee: $36,633.66
KEY PEOPLE |
 |
John W. Holaday
CEO
Thomas P. Russo
CFO
CONTACT INFO |
 |
9640 Medical Center Dr.
Rockville, MD 20850
US
Phone: 301-217-9858
Fax: 301-217-9594
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |